^
    Back
    Association details:
    Biomarker:CLDN18.2 expression
    Cancer:Solid Tumor
    Drug:givastomig (TJ-CD4B) (CLDN18.2 inhibitor, CD137 agonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    SITC 2021
    Title:

    TJ-CD4B (ABL111), a Claudin18.2-targeted 4-1BB tumor engager induces potent tumor-dependent immune response without dose-limiting toxicity in preclinical studies

    Published date:
    11/09/2021
    Excerpt:
    TJ-CD4B (ABL111) is a novel CLDN18.2 dependent 4-1BB bispecific agonist antibody that induced T cell activation and memory response in tumor with CLDN18.2 expression, leading to a strong anti-tumor activity in vivo. 
    DOI:
    10.1136/jitc-2021-SITC2021.702